Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
L3Harris
LHX
|
$148M |
| 2 |
GE HealthCare
GEHC
|
$118M |
| 3 |
Atlassian
TEAM
|
$101M |
| 4 |
Monster Beverage
MNST
|
$81.1M |
| 5 |
PACCAR
PCAR
|
$48.1M |
Top Sells
| 1 |
Apple
AAPL
|
$360M |
| 2 |
Microsoft
MSFT
|
$199M |
| 3 |
NVIDIA
NVDA
|
$99.2M |
| 4 |
Amazon
AMZN
|
$85.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$83.8M |
Sector Composition
| 1 | Technology | 28.64% |
| 2 | Healthcare | 14.81% |
| 3 | Consumer Discretionary | 11.76% |
| 4 | Industrials | 9.45% |
| 5 | Communication Services | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Allbirds
BIRD
$52.4M
| $249K | ﹤0.01% | 207,700 -23,600 | -10% | -$28.3K |
|
|
GTHX
2627
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $248K | ﹤0.01% | 92,600 -10,900 | -11% | -$29.2K |
|
2628
Fulcrum Therapeutics
FULC
$351M
| $247K | ﹤0.01% | 86,500 -3,100 | -3% | -$8.84K |
|
2629
Expensify
EXFY
$182M
| $241K | ﹤0.01% | 29,600 -2,500 | -8% | -$20.4K |
|
2630
Adicet Bio
ACET
$59.9M
| $240K | ﹤0.01% | 41,600 -1,900 | -4% | -$10.9K |
|
2631
C4 Therapeutics
CCCC
$185M
| $232K | ﹤0.01% | 73,900 -8,700 | -11% | -$27.3K |
|
2632
Rackspace Technology
RXT
$302M
| $214K | ﹤0.01% | 113,900 -9,800 | -8% | -$18.4K |
|
2633
PMV Pharmaceuticals
PMVP
$74.2M
| $212K | ﹤0.01% | 44,400 -3,800 | -8% | -$18.1K |
|
2634
ALX Oncology
ALXO
$62.7M
| $179K | ﹤0.01% | 39,500 -3,500 | -8% | -$15.8K |
|
2635
ESS Tech
GWH
$20.8M
| $173K | ﹤0.01% | 124,700 -1,100 | -0.9% | -$1.53K |
|
2636
Veru
VERU
$47.6M
| $160K | ﹤0.01% | 138,300 -16,600 | -11% | -$19.3K |
|
2637
Telos
TLS
$449M
| $158K | ﹤0.01% | 62,300 -600 | -1% | -$1.52K |
|
|
HYZN
2638
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $131K | ﹤0.01% | 160,500 -15,200 | -9% | -$12.4K |
|
|
CASA
2639
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $126K | ﹤0.01% | 99,600 -900 | -0.9% | -$1.14K |
|
|
SI
2640
DELISTED
Silvergate Capital Corporation
SI
| $111K | ﹤0.01% | 68,400 -8,000 | -10% | -$13K |
|
|
BBBY
2641
DELISTED
Bed Bath & Beyond Inc
BBBY
| $69.1K | ﹤0.01% | 161,700 +800 | +0.5% | +$342 |
|
|
SATX
2642
DELISTED
SatixFy Communications
SATX
| $40K | ﹤0.01% | +59,100 | New | +$40K |
|
|
CYXT
2643
DELISTED
Cyxtera Technologies, Inc. Class A Common Stock
CYXT
| $31.9K | ﹤0.01% | 104,300 -900 | -0.9% | -$275 |
|
2644
Quantum-Si Incorporated
QSI
$227M
| – | – | -201,900 | Closed | -$369K |
|
2645
Alto Ingredients
ALTO
$87.5M
| – | – | -175,700 | Closed | -$506K |
|
2646
BARK
BARK
$153M
| – | – | -142,300 | Closed | -$212K |
|
2647
Bioventus
BVS
$495M
| – | – | -71,400 | Closed | -$186K |
|
2648
Cardlytics
CDLX
$54.3M
| – | – | -80,900 | Closed | -$468K |
|
2649
Celularity
CELU
$94.4M
| – | – | -120,236 | Closed | -$155K |
|
2650
Generation Bio
GBIO
$40.4M
| – | – | -106,800 | Closed | -$420K |
|